These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953 [TBL] [Abstract][Full Text] [Related]
3. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954 [TBL] [Abstract][Full Text] [Related]
4. Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017 [TBL] [Abstract][Full Text] [Related]
5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
6. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682 [TBL] [Abstract][Full Text] [Related]
7. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197 [No Abstract] [Full Text] [Related]
8. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692 [TBL] [Abstract][Full Text] [Related]
9. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357 [TBL] [Abstract][Full Text] [Related]
10. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138 [TBL] [Abstract][Full Text] [Related]
11. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177 [TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D; J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529 [TBL] [Abstract][Full Text] [Related]
16. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Ito S; Yukawa T; Uetake S; Yamauchi M Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172 [TBL] [Abstract][Full Text] [Related]
17. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462 [TBL] [Abstract][Full Text] [Related]